Vantrexa · SCLC · Germany · Thoracic medical oncologist · captured by James Whitfield on 07 Jul 2026 · reviewed by Dr. Marcus Lindqvist on 11 Jul 2026
Verbatim as captured; never edited
Thoracic medical oncologist at Uniklinik Köln raised pd-l1 testing turnaround during a scientific exchange. They indicated this influences their current prescribing approach.
Human-approved by Dr. Marcus Lindqvist on 11 Jul 2026
PD-L1 testing turnaround: request for data reported by thoracic medical oncologist (DE).
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 4 | 20% | 16.0 |
| Scientific importance | 2 | 15% | 6.0 |
| Urgency | 3 | 15% | 9.0 |
| Novelty | 3 | 10% | 6.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 2 | 5% | 2.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | High 69 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
06 Jul 2026 · Dr. Mariana Sato, Uniklinik Köln · MSL James Whitfield
Insight
Reviewed 11 Jul 2026 by Dr. Marcus Lindqvist
Action
Medical education program · Dr. Sophie Laurent · In progress
Decision
Outcome
Closure